Turning fat into muscle: can this be an alternative to anti-obesity drugs such as semaglutide?

J Physiol. 2024 Apr;602(8):1655-1658. doi: 10.1113/JP286430. Epub 2024 Mar 1.
No abstract available

Keywords: GLP‐1 receptor agonists; diabetes mellitus; hypertrophy; muscle atrophy; obesity; skeletal muscle.

MeSH terms

  • Anti-Obesity Agents* / pharmacology
  • Anti-Obesity Agents* / therapeutic use
  • Diabetes Mellitus, Type 2*
  • Glucagon-Like Peptide-1 Receptor
  • Glucagon-Like Peptides / therapeutic use
  • Humans
  • Hypoglycemic Agents
  • Muscles

Substances

  • semaglutide
  • Anti-Obesity Agents
  • Glucagon-Like Peptides
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents